Our results indicated that low dose of CC1007 could arrest the cell cycle at the G0/G1 phase and suppress cyclin E1, cyclin A, and c-Myc protein signaling or upregulate p21CIP1 expression in BCR-ABL1− pre-B-ALL cell lines, confirming that low dose of CC1007 could promote the differentiation signal in pre-B-ALL cells. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.